Compare Cassava Sciences Inc (FLNA) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Tapestry, Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Tapestry, Inc. trades at $143.72 (market cap $28.34B). The key difference: Tapestry, Inc. is far larger — about 533.3× Cassava Sciences Inc's market cap, and Tapestry, Inc. pays a 1.14% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TPR | |
|---|---|---|
Market Cap | $53.14M | $28.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $160.49 |
52-Week Low | $1.09 | $95.69 |
Enterprise Value | -$33.43M | $31.19B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
TPR stock trades at $143.67, up 6.14% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $7.01B in 2025 with net income of $183.20M, though margins compressed from prior years. Recent quarters show consistent earnings beats, and analyst sentiment remains strongly positive with a consensus price target of $184.14. Cash flow trends indicate volatility, with 2025 net cash flow negative $5.02B due to financing activities.
Outlook: Strong buy ratings and earnings momentum support upside potential, but elevated valuation ratios and technical bearishness pose near-term risks. Key opportunities include digital growth and brand strength, while risks involve margin pressure and high debt levels. Investors should weigh robust analyst confidence against fundamental headwinds for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
